GUILIN SANJIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.81 CNY | -8.42% |
|
-9.44% | -4.69% |
| 04-26 | Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 | CI |
| 04-25 | Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 2.67B 369M 504M | Sales 2025 * | 3.1B 427M 584M | Capitalization | 8.11B 1.12B 1.53B |
|---|---|---|---|---|---|
| Net income 2024 * | 580M 80.05M 109M | Net income 2025 * | 682M 94.12M 129M | EV / Sales 2024 * | 3.04 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.62 x |
| P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
11.9
x | Employees | 2,720 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -8.42% | ||
| 1 week | -9.44% | ||
| Current month | -3.02% | ||
| 1 month | -2.61% | ||
| 3 months | +3.29% | ||
| 6 months | -3.96% | ||
| Current year | -4.69% |
1 week
13.57
15.47
1 month
13.5715.73
Current year
11.2815.73
1 year
11.2821.67
3 years
10.5921.67
5 years
10.5921.67
10 years
10.5937.49
| Managers | Title | Age | Since |
|---|---|---|---|
Xun Zou
CHM | Chairman | 48 | 10-12-21 |
Yuan Gang Xie
DFI | Director of Finance/CFO | 63 | 07-12-20 |
Zhun Zou
BRD | Director/Board Member | 44 | 13-07-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuan Gang Xie
DFI | Director of Finance/CFO | 63 | 07-12-20 |
Ling Xia Mo
BRD | Director/Board Member | 60 | 19-04-12 |
Xun Zou
CHM | Chairman | 48 | 10-12-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 13.81 | -8.42% | 15,747,860 |
| 24-04-25 | 15.08 | -0.07% | 3,820,111 |
| 24-04-24 | 15.09 | -0.79% | 3,484,500 |
| 24-04-23 | 15.21 | +0.46% | 4,348,651 |
| 24-04-22 | 15.14 | -0.72% | 4,857,051 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.81
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.69% | 1.12B | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 002275 Stock
